Comparative Pharmacology
Head-to-head clinical analysis: FERRISELTZ versus MONOFERRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERRISELTZ versus MONOFERRIC.
FERRISELTZ vs MONOFERRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferric iron (Fe3+) from ferric citrate reduces phosphate absorption by forming insoluble ferric phosphate complexes in the gastrointestinal tract, reducing serum phosphate levels. Iron is absorbed and incorporated into hemoglobin.
Monomeric ferric iron replaces iron stores and is incorporated into hemoglobin, myoglobin, and enzymes, supporting erythropoiesis and oxygen transport.
325-650 mg orally once daily; ferrous sulfate 325 mg (equivalent to 65 mg elemental iron).
100-200 mg elemental iron intravenously as a single dose, repeated weekly until iron stores are replete. Typical total dose is 1-2 g.
None Documented
None Documented
Not applicable for iron absorption; serum iron levels peak at 1-2 hours post-dose and decline with a half-life of approximately 6 hours, reflecting gastrointestinal absorption and distribution.
Terminal half-life: 10-14 hours for ferric carboxymaltose core; clinical effect persists for weeks due to iron utilization
Ferric citrate is primarily eliminated via feces as unabsorbed drug (approximately 70-80%). A small fraction is absorbed and excreted renally (less than 1% of ingested dose).
Renal: <1% unchanged; Biliary/fecal: >99% as iron in RBC turnover and storage
Category C
Category C
Iron Supplement
Iron Supplement